PolicyWinds
Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on. How labels work
California · 2025-2026 Regular Session

AB260 Sexual and reproductive health care.

Direction

Abortion medication abortionAI label

Expands abortion access model confidence 95%

Expands protections and access for medication abortion (including mifepristone) by shielding providers, pharmacists, clinics, and facilities from liability or discipline for off-label use, dispensing without certain labels, manufacturing, transport, and related acts lawful in CA; requires insurance/

a pharmacist may, at their discretion, dispense brand name or generic mifepristone or any drug used for medication abortion without the name of the patient as required in paragraph (3) of subdivision (a), the name of the prescriber as required in paragraph (4) of subdivision (a), or the name and address of the pharmacy as required in paragraph (6) of subdivision (a)

✓ Quote verified word for word in the bill text

Abortion travel interstate shieldAI label

Expands abortion access model confidence 90%

Expands interstate shield protections for abortion by prohibiting actions against CA-licensed practitioners, clinics, or facilities for acts relating to mifepristone or medication abortion drugs that are lawful in CA, even if based on out-of-state convictions or laws; bars sharing records with out

the laws of another state or federal actions that interfere with the ability of a practitioner to prescribe, furnish, order, or administer brand name or generic mifepristone or any drug used for medication abortion if that action is lawful under the laws of the state, are against the public policy of this state.

✓ Quote verified word for word in the bill text

Abortion provider clinic regulationAI label

Expands abortion access model confidence 85%

Reduces regulatory burdens and restrictions on abortion providers and clinics by prohibiting denial of licensure, disciplinary actions, or other penalties for acts relating to mifepristone or medication abortion drugs lawful in CA, and by authorizing regulations to exclude such drugs from certain FD

The board shall not suspend a license, revoke a license, or otherwise take disciplinary action against a licen

✓ Quote verified word for word in the bill text

Abortion funding insuranceAI label

Expands abortion access model confidence 90%

Expands insurance coverage mandates for mifepristone and medication abortion drugs by prohibiting limits or exclusions based on off-label use or REMS variations (with narrow exception) and requiring coverage even without FDA approval if specified conditions are met.

prohibit a health care service plan contract or a group or individual health insurance policy or certificate that covers prescription drugs from limiting or excluding coverage for brand name or generic mifepristone solely on the basis that the drug is prescribed for a use that is different from the use for which that drug has been approved for marketing by the FDA or that varies from an approved risk evaluation and mitigation strategy

✓ Quote verified word for word in the bill text

  1. Filed (completed)
  2. Committee (completed)
  3. Passed one chamber (completed)
  4. Passed both (completed)
  5. Governor (completed)
  6. Law

Stage: Law · step 6 of 6

Last action
2025-09-26: Chaptered by Secretary of State - Chapter 136, Statutes of 2025.
Filed
2025-01-16
Sponsor
Cecilia Aguiar-Curry D, Darshana Patel D + 18 cosponsors (18 D)
Read official text (Chaptered)Legislature pageLegiScan

Why the model tagged it this way: The bill primarily addresses medication abortion access and protections in response to federal uncertainties around mifepristone. It repeals obsolete criminal provisions, adds shields against out-of-state or federal interference, allows flexible dispensing and record-keeping for abortion drugs, prohibits discipline for off-label use or related acts lawful in CA, mandates insurance coverage, and extends liability protections. All substantive provisions fall under abortion topic subtags; no provisions address firearms, transgender issues, or immigration enforcement.

Related bills

Hearings and calendar

Votes

DateChamberMotionYea-Nay
2025-04-08ADo pass and be re-referred to the Committee on [Business and Professions]12-1Passed
2025-04-29ADo pass and be re-referred to the Committee on [Appropriations]14-1Passed
2025-05-14ADo pass11-4Passed
2025-05-19AAB 260 Aguiar-Curry Assembly Third Reading61-11Passed
2025-06-11SDo pass as amended, but first amend, and re-refer to the Committee on [Business, Professions and Economic Development]6-1Passed
2025-06-23SDo pass, but first be re-referred to the Committee on [Appropriations]8-2Passed
2025-07-07SPlaced on suspense file6-0Passed
2025-08-29SDo pass5-2Passed
2025-09-09SAssembly 3rd Reading AB260 Aguiar-Curry et al. By Limón Urgency Clause30-8Passed
2025-09-10AAB 260 Aguiar-Curry Concurrence - Urgency Added61-12Passed

Sponsors

Text versions

History (30 actions)
DateChamberAction
2025-09-26Chaptered by Secretary of State - Chapter 136, Statutes of 2025.
2025-09-26Approved by the Governor.
2025-09-22Enrolled and presented to the Governor at 3 p.m.
2025-09-10AUrgency clause adopted. Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 61. Noes 12. Page 3193.).
2025-09-09AIn Assembly. Concurrence in Senate amendments pending.
2025-09-09SRead third time. Urgency clause adopted. Passed. Ordered to the Assembly. (Ayes 30. Noes 8. Page 2736.).
2025-09-08SRead second time. Ordered to third reading.
2025-09-05SRead third time and amended. Ordered to second reading.
2025-08-29SRead second time. Ordered to third reading.
2025-08-29SFrom committee: Do pass. (Ayes 5. Noes 2.) (August 29).
2025-07-07SIn committee: Referred to APPR. suspense file.
2025-06-23SFrom committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 2.) (June 23). Re-referred to Com. on APPR.
2025-06-18SFrom committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on B. P. & E.D.
2025-06-13SRead second time and amended. Re-referred to Com. on B. P. & E.D.
2025-06-12SFrom committee: Amend, and do pass as amended and re-refer to Com. on B. P. & E.D. (Ayes 6. Noes 1.) (June 11).
2025-06-02SFrom committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH.
2025-05-28SReferred to Coms. on HEALTH and B. P. & E.D.
2025-05-20SIn Senate. Read first time. To Com. on RLS. for assignment.
2025-05-19ARead third time. Passed. Ordered to the Senate. (Ayes 61. Noes 11. Page 1601.)
2025-05-15ARead second time. Ordered to third reading.
2025-05-14AFrom committee: Do pass. (Ayes 11. Noes 4.) (May 14).
2025-04-29AFrom committee: Do pass and re-refer to Com. on APPR. (Ayes 14. Noes 1.) (April 29). Re-referred to Com. on APPR.
2025-04-29ACoauthors revised.
2025-04-09AFrom committee: Do pass and re-refer to Com. on B. & P. (Ayes 12. Noes 1.) (April 8). Re-referred to Com. on B. & P.
2025-04-09ACoauthors revised.
2025-03-18ARe-referred to Com. on HEALTH.
2025-03-17AFrom committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.
2025-03-17AReferred to Coms. on HEALTH and B. & P.
2025-01-17AFrom printer. May be heard in committee February 16.
2025-01-16ARead first time. To print.